Adjuvant therapy following resection of gastroenteropancreatic neuroendocrine tumors-There is hope, but more data are needed
- PMID: 32419171
- DOI: 10.1002/jso.25972
Adjuvant therapy following resection of gastroenteropancreatic neuroendocrine tumors-There is hope, but more data are needed
Comment on
-
The association of preoperative anxiety and depression with neurocognitive disorder following oncological surgery.J Surg Oncol. 2020 Mar;121(4):676-687. doi: 10.1002/jso.25836. Epub 2020 Jan 12. J Surg Oncol. 2020. PMID: 31930514 Free PMC article.
References
REFERENCES
-
- Yao JC, Fazio N, Singh S, et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet. 2016;387(10022):968-977.
-
- Rinke A, Müller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009;27(28):4656-4663.
-
- Frilling A, Modlin IM, Kidd M, et al. Recommendations for management of patients with neuroendocrine liver metastases. Lancet Oncol. 2014;15(1):e8-e21.14.
-
- Schmidbauer S, Ladurner R, Juckstock H, Trupka AW, Mussack T, Hallfeldt KK. Surgical and adjuvant therapy of neuroendocrine tumors of the gastrointestinal tract and their metastases. A retrospective analysis of personal patient group. Chirurg. 2001;72(8):945-952.
-
- Maire F, Hammel P, Kianmanesh R, et al. Is adjuvant therapy with streptozotocin and 5-fluorouracil useful after resection of liver metastases from digestive endocrine tumors? Surgery. 2009;145(1):69-75.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
